Skip to content

Accuracy Study for Enhanced Meter Feature

Accuracy Study for the Evaluation of Obtaining an Enhanced Meter Feature Using an AgaMatrix BGMS

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01885546
Enrollment
133
Registered
2013-06-25
Start date
2013-07-31
Completion date
2013-12-31
Last updated
2015-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Keywords

diabetes, glucose, glucometer

Brief summary

This enhanced meter feature raises awareness among patients by providing additional information regarding their glycemic control between Healthcare Professional visits. This information may facilitate increased dialogue between patient and Healthcare Professionals and can remind patients of the importance of glycemic control. This study will evaluate a user's ability to obtain the enhanced meter feature.

Interventions

Sponsors

AgaMatrix, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Type I or type II diabetes inclusive of the following populations: 1. Mixed insulin therapies 2. Basal insulin therapies 3. Continuous subcutaneous insulin infusion therapies 4. Multiple daily injection therapies 5. Non-insulin diabetic treatments (oral and injectable) 6. Life style (exercise and diet) diabetes management 7. New diagnosis of diabetes * Non diabetics * Able to speak and read English proficiently * Subjects must be willing to: 1. once a month, perform a 7 point blood glucose profile over the course of one day 2. perform fasting blood glucose tests every day 3. complete baseline and follow-up questionnaires 4. consent to baseline HbA1c assays

Exclusion criteria

* Pregnant * Hct \<20 or \>60 * Work for BGM competitor company (including, but not limited to Lifescan, Roche, Abbott) * Homeless * Incarcerated * Mentally ill * Employees or students of the Research Site, including the Principal Investigator, directly involved in the conduct of the protocol. * Has any condition that the Principal Investigator believes may interfere in the subject's participation in the study.

Design outcomes

Primary

MeasureTime frame
User's ability to obtain the enhanced meter feature16 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 17, 2026